IP Library › Granted Patent US 12,371,475
Granted Patent B2
US 12,371,475 · App. 17/555,616 · Granted Jul 29, 2025

Nucleic acids encoding anchor modified antibodies and uses thereof

Inventors: Jason Mastaitis (Yorktown Heights, NY); Andrew J. Murphy (Croton-on-Hudson, NY); John McWhirter (Savannah, GA); Vera Voronina (North Bethesda, MD); Jesper Gromada (Concord, MA)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/00A01K67/0275C07K14/58C07K14/72C07K16/26C12N9/22C12N15/11C12N15/907A01K2217/07A01K2227/105A01K2267/01C07K2317/56C07K2317/76C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,475
App. No.
17/555,616
Granted
Jul 29, 2025
Kind
B2
Abstract

Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.

Claims (71)

1. A recombinant nucleic acid molecule comprising a modified immunoglobulin (Ig) variable (V) gene segment that encodes an anchor-modified Ig polypeptide,

wherein the modified Ig V gene segment comprises a nucleic acid sequence encoding the anchor between a nucleic acid sequence encoding an Ig signal peptide and a nucleic acid sequence encoding the framework region (FR) 1, complementarity determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of a germline Ig V gene segment, or a variant thereof,

wherein the anchor-modified Ig polypeptide comprises, in operable linkage:

(i) the Ig signal peptide,

(ii) the anchor, and

(iii) the FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V gene segment, or a variant thereof,

wherein the anchor comprises a receptor binding portion of a non-immunoglobulin polypeptide of interest that binds a cognate receptor, and

optionally wherein the nucleic acid molecule lacks any other Ig V gene segments.

2. The recombinant nucleic acid molecule of claim 1 , wherein the Ig signal peptide is the Ig signal peptide of the germline Ig V gene segment, or the variant thereof.

3. The recombinant nucleic acid molecule of claim 1 , wherein the germline Ig V gene segment, or the variant thereof is a germline Ig heavy chain variable (V H ) gene segment, or a variant thereof such that

the modified Ig V gene segment is a modified Ig V H gene segment that comprises the nucleic acid sequence encoding the anchor between the nucleic acid sequence encoding the Ig signal peptide and the nucleic acid sequence encoding the framework region (FR) 1, complementarity determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of the germline Ig V H gene segment, or a variant thereof, and

the anchor-modified Ig polypeptide comprises in operable linkage:

(i) the Ig signal peptide,

(ii) the anchor, and

(iii) the FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V H gene segment, or a variant thereof.

4. The recombinant nucleic acid molecule of claim 1 , wherein the germline Ig V gene segment, or the variant thereof is a germline hV H 1-69 gene segment, or a variant thereof, optionally wherein the Ig signal peptide comprises the sequence MDWTWRFLFVVAAATGVQS (SEQ ID NO:7).

5. The recombinant nucleic acid molecule of claim 3 , comprising in operable linkage and from 5′ to 3′:

(I) the modified Ig V H gene segment,

(II) one or a plurality of Ig heavy chain diversity (D H ) gene segments, and

(III) one or a plurality of Ig heavy chain joining (J H ) gene segments.

6. The recombinant nucleic acid molecule of claim 5 , wherein

the one or a plurality of Ig D H gene segments of (II) comprises one, a plurality of, or all human Ig D H gene segments, and/or

the one or a plurality of Ig J H gene segments of (III) comprises one, a plurality of, or all human Ig J H gene segments.

7. The recombinant nucleic acid molecule of claim 5 , wherein the one or a plurality of Ig D H gene segments of (II) and the one or a plurality of Ig J H gene segments of (III) are recombined and form a rearranged Ig D H /J H sequence such that the recombinant nucleic acid molecule comprises in operable linkage and from 5′ to 3′:

the modified Ig V H gene segment and

the rearranged Ig D H /J H sequence.

8. The recombinant nucleic acid molecule of claim 7 , wherein the modified Ig V H gene segment and the rearranged Ig D H /J H sequence are recombined and form a rearranged Ig V H /D H /J H sequence that encodes an anchor-modified Ig V H domain,

wherein the anchor-modified Ig V H domain comprises in operable linkage:

(i) the Ig signal peptide,

(ii) the anchor, and

(iii) the FR1, complementarity determining region (CDR) 1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the rearranged Ig V H /D H /J H sequence.

9. The recombinant nucleic acid molecule of claim 3 , wherein the modified Ig V H gene segment is an unrearranged modified Ig V H gene segment.

10. The recombinant nucleic acid molecule of claim 5 , further comprising a nucleic acid sequence encoding an Ig heavy chain constant region (CH),

wherein the nucleic acid sequence encoding the Ig CH is downstream of and operably linked to

(I) the modified Ig V H gene segment,

(II) the one or a plurality of Ig D H gene segments, and

(III) the one or a plurality of Ig J H gene segments.

11. The recombinant nucleic acid molecule of claim 1 , wherein the germline Ig V gene segment or the variant thereof is a germline Ig light chain variable (V L ) gene segment or a variant thereof such that

the modified Ig V gene segment is a modified Ig V L gene segment that comprises the nucleic acid sequence encoding the anchor between the nucleic acid sequence encoding the Ig signal peptide and the nucleic acid sequence encoding the framework region (FR) 1, complementarity determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of the germline Ig V L gene segment or the variant thereof, and

the anchor-modified Ig polypeptide comprises in operable linkage:

(i) the Ig signal peptide,

(ii) the anchor, and

(iii) the FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V L gene segment or a variant thereof.

12. The recombinant nucleic acid molecule of claim 11 , comprising in operable linkage and from 5′ to 3′:

(I) the modified Ig V L gene segment, and

(II) one or a plurality of Ig light chain joining (J L ) gene segments.

13. The recombinant nucleic acid molecule of claim 12 , wherein the modified Ig V L gene segment and the one or a plurality of Ig J L gene segments are recombined and form a rearranged Ig VI/J L sequence that encodes an anchor-modified Ig V L domain,

wherein the anchor-modified Ig V L domain comprises in operable linkage:

(i) the Ig signal peptide,

(ii) the anchor, and

(iii) the FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the rearranged Ig V L /J L sequence.

14. The recombinant nucleic acid molecule of claim 12 , further comprising a nucleic acid sequence encoding an Ig light chain constant region (C L ),

wherein the nucleic acid sequence encoding the Ig C L is downstream of and operably linked to:

(I) the modified Ig V L gene segment and

(II) the one or a plurality of Ig J L gene segments.

15. The recombinant nucleic acid molecule of claim 1 , wherein the anchor comprises a linker that links the receptor binding portion of the non-immunoglobulin polypeptide of interest to the FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V gene segment, or a variant thereof.

16. The recombinant nucleic acid molecule of claim 15 , wherein the linker comprises the sequence GGGGS (SEQ ID NO:5).

17. The recombinant nucleic acid molecule of claim 1 , wherein the anchor comprises the natriuretic peptide receptor (NPR) binding portion of a natriuretic peptide (NP).

18. The recombinant nucleic acid molecule of claim 17 , wherein the NPR binding portion of the NP comprises the C-terminal tail of the NP.

19. The recombinant nucleic acid molecule of claim 17 , wherein the NP is atrial natriuretic peptide (ANP).

20. The recombinant nucleic acid molecule of claim 1 , wherein the anchor comprises the sequence NSFRY (SEQ ID NO:3).

21. The recombinant nucleic acid molecule of claim 1 , comprising a sequence selected from the group consisting of the sequence set forth as SEQ ID NO:8 or a degenerate variant thereof, the sequence set forth as SEQ ID NO:10 or a degenerate variant thereof, the sequence set forth as SEQ ID NO:11 or a degenerate variant thereof, and the sequence set forth as SEQ ID NO:12 or a degenerate variant thereof.

22. A targeting vector comprising the recombinant nucleic acid molecule of claim 1 , wherein the targeting vector further comprises 5′ and 3′ homology arms that target a non-human Ig heavy chain locus such that upon homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus comprises the recombinant nucleic acid molecule upstream of and in operable linkage to a non-human Ig CH at the non-human Ig heavy chain locus, optionally wherein the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus and/or wherein the non-human Ig heavy chain locus comprises a human or humanized immunoglobulin heavy chain variable region, a deletion of endogenous Ig V H , D H , and/or J H gene segments, or a combination thereof.

23. A targeting vector comprising the recombinant nucleic acid molecule of claim 1 , wherein the targeting vector further comprises 5′ and 3′ homology arms that target a non-human Ig heavy chain locus such that upon homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus comprises the recombinant nucleic acid molecule in operable linkage to a non-human Ig heavy chain regulatory sequence at the non-human Ig heavy chain locus, optionally wherein the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus and/or wherein the non-human Ig heavy chain locus comprises a human or humanized immunoglobulin heavy chain variable region, a deletion of endogenous Ig V H , D H , and/or J H gene segments, or a combination thereof.

24. A targeting vector comprising the recombinant nucleic acid molecule of claim 1 , wherein the targeting vector further comprises 5′ and 3′ homology arms that target a non-human Ig light chain locus such that upon homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus comprises the recombinant nucleic acid molecule upstream of and in operable linkage to a non-human Ig C L at the non-human Ig light chain locus, optionally wherein the non-human Ig light chain locus is an endogenous rodent Ig light chain locus and/or wherein the non-human Ig light chain locus comprises a human or humanized immunoglobulin light chain variable region, a deletion of endogenous Ig V L and/or J L gene segments, or a combination thereof.

25. A targeting vector comprising the recombinant nucleic acid molecule of claim 1 , wherein the targeting vector further comprises 5′ and 3′ homology arms that target a non-human Ig light chain locus such that upon homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus comprises the recombinant nucleic acid molecule in operable linkage to a non-human Ig light chain regulatory sequence at the non-human Ig light chain locus, optionally wherein the non-human Ig light chain locus is an endogenous rodent Ig light chain locus and/or wherein the non-human Ig light chain locus comprises a human or humanized immunoglobulin light chain variable region, a deletion of endogenous Ig V L and/or J L gene segments, or a combination thereof.

26. An antigen-binding protein comprising an anchor-modified Ig polypeptide encoded by the recombinant nucleic acid molecule of claim 1 , optionally:

wherein the mass of each antigen-binding protein confirms the presence of the anchor-modified Ig polypeptide,

wherein the mass of each antigen-binding protein is determined by Matrix-Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry, or

wherein the mass of each antigen-binding protein confirms the presence of the anchor-modified Ig polypeptide and the mass of each antigen-binding protein is determined by Matrix-Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry.

27. The antigen-binding protein comprising the anchor-modified Ig polypeptide of claim 26 comprising an amino acid sequence set forth as SEQ ID NO:3 at its N-terminus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2025
From: MASTAITIS, JASON; MURPHY, ANDREW J.; MCWHIRTER, JOHN; VORONINA, VERA; GROMADA, JESPER
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 070775/0278 →
Continuity (3)
Provisional Application 63219402 · Jul 8, 2021
Provisional Application 63129893 · Dec 23, 2020
Related Publication 20220195014A1 · Jun 23, 2022
References Cited (148)
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5698679A · Nemazee et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5807706A · Carter et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5821333A · Carter et al. · 1998 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6586251B2 · Economides et al. · 2003 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6998514B2 · Bruggemann et al. · 2006 [cited by applicant]
US 7582298B2 · Stevens et al. · 2009 [cited by applicant]
US 7642228B2 · Carter et al. · 2010 [cited by applicant]
US 7795494B2 · Ghayur · 2010 [cited by applicant]
US 7910798B2 · Tanamachi et al. · 2011 [cited by applicant]
US 8232449B2 · Tanamachi et al. · 2012 [cited by applicant]
US 8502018B2 · Murphy et al. · 2013 [cited by applicant]
US 8642835B2 · Macdonald et al. · 2014 [cited by applicant]
US 8679785B2 · Carter et al. · 2014 [cited by applicant]
US 8697940B2 · Macdonald et al. · 2014 [cited by applicant]
US 8703485B2 · Buelow · 2014 [cited by applicant]
US 8754287B2 · Macdonald et al. · 2014 [cited by applicant]
US 8791323B2 · Murphy et al. · 2014 [cited by applicant]
US 8809051B2 · Jakobovits et al. · 2014 [cited by applicant]
US 8907157B2 · Buelow · 2014 [cited by applicant]
US 9035128B2 · Macdonald et al. · 2015 [cited by applicant]
US 9145588B2 · Throsby et al. · 2015 [cited by applicant]
US 9204624B2 · McWhirter et al. · 2015 [cited by applicant]
US 9206263B2 · Macdonald et al. · 2015 [cited by applicant]
US 9226484B2 · Macdonald et al. · 2016 [cited by applicant]
US 9301510B2 · McWhirter et al. · 2016 [cited by applicant]
US 9332742B2 · McWhirter et al. · 2016 [cited by applicant]
US 9334334B2 · McWhirter et al. · 2016 [cited by applicant]
US 9447177B2 · Bradley et al. · 2016 [cited by applicant]
US 9516868B2 · Macdonald et al. · 2016 [cited by applicant]
US 9551124B2 · Bourgeois · 2017 [cited by applicant]
US 9580491B2 · Green et al. · 2017 [cited by applicant]
US 9796788B2 · McWhirter et al. · 2017 [cited by applicant]
US 9801362B2 · McWhirter et al. · 2017 [cited by applicant]
US 9969814B2 · McWhirter et al. · 2018 [cited by applicant]
US 10130081B2 · McWhirter et al. · 2018 [cited by applicant]
US 10143186B2 · McWhirter et al. · 2018 [cited by applicant]
US 20030232395A1 · Hufton · 2003 [cited by examiner]
US 20070004909A1 · Johnson et al. · 2007 [cited by applicant]
US 20090060910A1 · Johnson et al. · 2009 [cited by applicant]
US 20100146647A1 · Logtenberg et al. · 2010 [cited by applicant]
US 20110195454A1 · McWhirter et al. · 2011 [cited by applicant]
US 20120021409A1 · McWhirter et al. · 2012 [cited by applicant]
US 20120164068A1 · Hudson · 2012 [cited by examiner]
US 20120192300A1 · Babb et al. · 2012 [cited by applicant]
US 20130045492A1 · Babb et al. · 2013 [cited by applicant]
US 20130096287A1 · Macdonald · 2013 [cited by examiner]
US 20130167256A1 · Green et al. · 2013 [cited by applicant]
US 20130185821A1 · Babb et al. · 2013 [cited by applicant]
US 20130195849A1 · Spreter von Kreudenstein et al. · 2013 [cited by applicant]
US 20130198880A1 · McWhirter et al. · 2013 [cited by applicant]
US 20130219535A1 · Wabl et al. · 2013 [cited by applicant]
US 20130302836A1 · McWhirter et al. · 2013 [cited by applicant]
US 20130326647A1 · Macdonald et al. · 2013 [cited by applicant]
US 20130333057A1 · Macdonald · 2013 [cited by examiner]
US 20140013456A1 · McWhirter et al. · 2014 [cited by applicant]
US 20150059009A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150113668A1 · Bruggemann et al. · 2015 [cited by applicant]
US 20150289489A1 · Macdonald et al. · 2015 [cited by applicant]
US 20150313193A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150376628A1 · Schoenherr et al. · 2015 [cited by applicant]
US 20160145646A1 · Frendewey et al. · 2016 [cited by applicant]
US 20160177339A1 · Voronina et al. · 2016 [cited by applicant]
US 20180125043A1 · Guo et al. · 2018 [cited by applicant]
US 20180244804A1 · Macdonald et al. · 2018 [cited by applicant]
EP 3128009B1 · 2020 [cited by applicant]
WO 2007117410A2 · 2007 [cited by applicant]
WO 2008124086A2 · 2008 [cited by applicant]
WO 2008151081A1 · 2008 [cited by applicant]
WO 2009114400A1 · 2009 [cited by applicant]
WO 2009157771A2 · 2009 [cited by applicant]
WO 2010039900A2 · 2010 [cited by applicant]
WO 2011004192A1 · 2011 [cited by applicant]
WO 2011097603A1 · 2011 [cited by applicant]
WO 2011123708A2 · 2011 [cited by applicant]
WO 2011163314A1 · 2011 [cited by applicant]
WO 2012148873A2 · 2012 [cited by applicant]
WO 2013134263A1 · 2013 [cited by applicant]
WO 2013184761A1 · 2013 [cited by applicant]
WO 2014093908A2 · 2014 [cited by applicant]
WO 2014160179A1 · 2014 [cited by applicant]
WO 2014160202A1 · 2014 [cited by applicant]
WO 2017210586A1 · 2017 [cited by applicant]
WO 2019113065A1 · 2019 [cited by applicant]
WO WO2020072937A1 · 2020 [cited by examiner]
Alt et al. “Immunoglobulin genes in transgenic mice,” Trends Genet., 1985, 1:231-236. [cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool,” J. Mol. Biol., 1990, 215(3): 403-410. [cited by applicant]
Altschul and Gish, “[27] Local Alignment Statistics,” Methods in Enzymol., 1996, 266:460-480. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 1997, 25:3389-3402. [cited by applicant]
Auerbach et al. “Establishment and Chimera Analysis of 129/SvEv- and C57BL/6-Derived. Mouse Embryonic Stem Cell Lines,” Biotechniques, 2000, 29(5):1024-1028, 1030, 1032. [cited by applicant]
Azzazy and Highsmith “Phage display technology: clinical applications and recent innovations,” Clin. Biochem., 2002, 35:425-445. [cited by applicant]
Barbié and Lefranc, “The Human Immunoglobulin Kappa Variable (IGKV) Genes and Joining (IGKJ) Segments,” Exp. Clin. Immunogenet., 1998, 15:171-183. [cited by applicant]
Collins and Bercik, “Intestinal bacteria influence brain activity in healthy humans,” Nature Reviews, Gastroenterology & Hepatology, Jun. 2013, 10:326-327. [cited by applicant]
Dechiara et al. “VelociMouse: Fully ES Cell-Derived FO-Generation Mice Obtained from the Injection of ES Cells into Eight-Cell-Stage Embryos,” Methods Mol. Biol., 2009, 530:311-324. [cited by applicant]
Dechiara et al. “Producing Fully ES Cell-Derived Mice from Eight-Cell Stage Embryo Injections,” Methods Enzymol., 2010, 476:285-294. [cited by applicant]
Festing et al. “Revised nomenclature for strain 129 mice,” Mammalian Genome, 1999, 10:836. [cited by applicant]
Frendewey et al. “The Loss-of-Allele Assay for ES Cell Screening and Mouse Genotyping,” Methods Enzymol., 2010, 476:295-307. [cited by applicant]
Gavilondo and Larrick, “Antibody Engineering at the Millennium,” BioTechniques, 2002, 29:128-145. [cited by applicant]
Gonnet et al., “Exhaustive Matching of the Entire Protein Sequence Database,” Science, Jun. 5, 1992, 256:1443-1445. [cited by applicant]
Green et al. “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,” Nat. Genet., 1994, 7:13-21. [cited by applicant]
He et al. “Structural Determinants of Natriuretic Peptide Receptor Specificity and Degeneracy,” J. Mol. Biol., 2006, 361:698-714. [cited by applicant]
Hiom and Gellert, “Assembly of a 12/23 Paired Signal Complex: A Critical Control Point in V(D)J Recombination,” Mol. Cell., 1998, 1(7):1011-1019. [cited by applicant]
Hoogenboom, “Designing and optimizing library selection strategies for generating high-affinity antibodies,” TIB Tech., 1997, 15:62-70. [cited by applicant]
Hoogenboom and Chames, “Natural and designer binding sites made by phage display technology,” Immunology Today, 2000, 21:371-378. [cited by applicant]
Jakobovits et al. “From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice,” Nat. Biotechnol., 2007, 25:1134-1143. [cited by applicant]
Jaubert et al. “Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3),” PNAS, 1999, 96(18) 10278-10283. [cited by applicant]
Kellermann and Green “Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics,” Current Opinion in Biotechnology, 2002, 13:593-597. [cited by applicant]
Kitano et al., “Production of polyclonal antibody specific for human natriuretic peptide receptor B,” Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, Aug. 14, 1996, 194(2):147-153. [cited by applicant]
Lakso et al., “Targeted oncogene activation by site-specific recombination in transgenic mice,” Proc. Natl. Acad. Sci. USA, 1992, 89:6232-6236. [cited by applicant]
Lee et al. “Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery,” Nature Biotechnology, 2014, 32(4):356 (12 pages). [cited by applicant]
Lefranc, “Nomenclature of the Human Immunoglobulin Heavy (IGH) Genes,” Exp. Clin. Immunogenet., 2001, 18:100-116. [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev. Comp. Immunol., 2003, 27:55-77. [cited by applicant]
Lefranc and Lefranc “Immunoglobulins or Antibodies: IMGT® Bridging Genes, Structures and Functions,” Biomedicines, 2020, 8(319):1-117. [cited by applicant]
Li et al. “Minimization of a Peptide Hormone,” Science, 1995, 270:1657-1660. [cited by applicant]
Little et al. Of mice and men: hybridoma and recombinant antibodies, Immunology Today, 2000, 21(8):364-370. [cited by applicant]
Lonberg et al. “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, 1994, 368:856-859. [cited by applicant]
Macdonald et al. “Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes,” Proc. Natl. Acad. Sci. USA, 2014, 111:5147-5152 with supplemental pages (18 pages). [cited by applicant]
Mangiafico et al. “Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics,” European Heart Journal, 2013, 34:886-893. [cited by applicant]
Martinez and Lefranc “The Mouse ( [cited by applicant]
Matsukawa et al., “The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system,” Proc. Natl. Acad. Sci. USA, 1999, 96:7403-7408. [cited by applicant]
Misono “Natriuretic peptides and their receptors,” Febs J., 2011, 278:1791. [cited by applicant]
Misono et al. “Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase,” Febs J., 2011, 278:1818-1829. [cited by applicant]
Murphy et al., “Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice,” Proc. Natl. Acad. Sci. U. S. A., 2014, 111(14):5153-5158 with supplemental pages (12 page… [cited by applicant]
O'Gorman et al, “Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells,” Science, 1991, 251:1351-1355. [cited by applicant]
Pallarès et al., “The Human Immunoglobulin Lambda Variable (IGLV) Genes and Joining (IGLJ) Segments,” Exp. Clin. Immunogenet., 1998, 15:8-18. [cited by applicant]
Pallarès et al.,“The Human Immunoglobulin Heavy Variable Genes,” Exp. Clin. Immunogenet., 1999, 16:36-60. [cited by applicant]
Pandit et al. “Natriuretic peptides: Diagnostic and therapeutic use,” Ind. J. Endocrinol. Metab., 2011, 15(4):S345-S353. [cited by applicant]
Potter et al., “Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions,” Endocrine Reviews, 2006, 27(1):47-72. [cited by applicant]
Poueymirou et al. “F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immedite phenotypic analyses,” Nat. Biotechnol., 2007, 25:91-99. [cited by applicant]
Ramsden et al., “Conservation of sequence in recombination signal sequence spacers,” Nuc. Acids Res., 1994, 22(10):1785-1796. [cited by applicant]
Ruiz et al. “The Human Immunoglobulin Heavy Diversity (IGHD) and Joining (IGHJ) Segments,” Exp. Clin. Immunogenet., 1999, 16:173-184. [cited by applicant]
Taylor et al., “A transgenic mouse that expresses a diversity of human sequence heavy chain and light chain immunoglobulins,” Nucl. Acids Res., 1992, 20:6287-6295. [cited by applicant]
Tian et al. “Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires,” Cell, 2016, 166:1471-1484. [cited by applicant]
Tomizuka et al. “Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies,” PNAS USA, 2000, 97:722-727. [cited by applicant]
Tscheuschner et al. “Fast Confirmation of Antibody Identity by MALDI-TOF MS Fingerprints,” Antibodies, 2020, 9(2):8 (17 pages). [cited by applicant]
Valenzuela et al. “High-throughput engineering of the mouse genome coupled with high-resolution expression analysis,” Nature Biotech., 2003, 21(6):652-659. [cited by applicant]
Wang and Stollar “Human immunoglobulin variable region gene analysis by single cell RT-PCR,” Journal of Immunological Methods, 2000, 244:217-225. [cited by applicant]
Wu et al., “Structure and Function of Peptide-Binding G Protein-Coupled Receptors,” J. Mol. Biol., 2017, 429:2726-2745. [cited by applicant]
Zhang et al., “Pentamerization of Single-domain Antibodies from Phage Libraries: A Novel Strategy for the Rapid Generation of High-avidity Antibody Reagents,” Journal of Molecular Biology, Academic Press, United Kingdom… [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report with respect to PCT/US2021/064263, dated Apr. 28, 2022. [cited by applicant]